UA84749C2 - Normal;heading 1;heading 2;PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES - Google Patents
Normal;heading 1;heading 2;PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASESInfo
- Publication number
- UA84749C2 UA84749C2 UAA200611678A UAA200611678A UA84749C2 UA 84749 C2 UA84749 C2 UA 84749C2 UA A200611678 A UAA200611678 A UA A200611678A UA A200611678 A UAA200611678 A UA A200611678A UA 84749 C2 UA84749 C2 UA 84749C2
- Authority
- UA
- Ukraine
- Prior art keywords
- heading
- treatment
- normal
- receptor antagonists
- inflammatory diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
- C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Disclosed herein are compounds represented by Structural Formula: (I) and (I-А). Also disclosed is the use of such compounds for inhibiting the G-protein coupled receptor referred to as chemoattractant receptor-homologous molecule expressed on Th2, or simply "CRTH2" for the treatment of inflammatory disorders. The variables in Structural Formula (I) and (I-А) are defined herein.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56041004P | 2004-04-07 | 2004-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA84749C2 true UA84749C2 (en) | 2008-11-25 |
Family
ID=34965223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200611678A UA84749C2 (en) | 2004-04-07 | 2005-04-07 | Normal;heading 1;heading 2;PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1740547A1 (en) |
JP (1) | JP2007532555A (en) |
KR (1) | KR20070002085A (en) |
CN (1) | CN101018770A (en) |
AR (1) | AR048528A1 (en) |
AU (1) | AU2005233125A1 (en) |
BR (1) | BRPI0509668A (en) |
CA (1) | CA2561564A1 (en) |
CL (1) | CL2008000069A1 (en) |
CR (1) | CR8659A (en) |
EC (1) | ECSP066977A (en) |
IL (1) | IL178328A0 (en) |
MA (1) | MA28566B1 (en) |
MX (1) | MXPA06011540A (en) |
NO (1) | NO20065107L (en) |
RU (1) | RU2006138603A (en) |
TN (1) | TNSN06320A1 (en) |
TW (1) | TW200538127A (en) |
UA (1) | UA84749C2 (en) |
WO (1) | WO2005100321A1 (en) |
ZA (1) | ZA200608955B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0608553A2 (en) | 2005-02-24 | 2010-01-12 | Millennium Pharm Inc | pgd2 receptor antagonists for the treatment of inflammatory diseases |
EP1717235A3 (en) * | 2005-04-29 | 2007-02-28 | Bioprojet | Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands |
KR101020351B1 (en) | 2005-07-29 | 2011-03-08 | 에프. 호프만-라 로슈 아게 | Indol-3-yl-carbonyl-piperidin and piperazin derivatives |
DK2037967T3 (en) | 2006-06-16 | 2017-03-13 | Univ Pennsylvania | PROSTAGLANDIN-D2 RECEPTOR ANTAGONISTS FOR TREATMENT OF ANDROGENETIC ALOPECI |
JP2010501567A (en) | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 2- (pyrazin-2-yl) -thiazole and 2- (1H-pyrazole-3-) as stearoyl-CoA desaturase (SCD) inhibitors for the treatment of metabolic, cardiovascular and other disorders Yl) thiazole derivatives and related compounds |
JPWO2008029924A1 (en) | 2006-09-08 | 2010-01-21 | 大日本住友製薬株式会社 | Cyclic aminoalkylcarboxamide derivatives |
BRPI0718509A2 (en) | 2006-09-22 | 2015-09-29 | Novartis Ag | heterocyclic organic compounds |
JP2010513403A (en) | 2006-12-20 | 2010-04-30 | ノバルティス アーゲー | 2-Substituted 5-membered heterocycles as SCD inhibitors |
WO2009041072A1 (en) | 2007-09-27 | 2009-04-02 | Kowa Company, Ltd. | Prophylactic and/or therapeutic agent for anemia, comprising tetrahydroquinoline compound as active ingredient |
CA2707785C (en) | 2007-12-14 | 2015-11-03 | Pulmagen Therapeutics (Asthma) Limited | Indoles and their therapeutic use |
JP2011102241A (en) * | 2008-03-04 | 2011-05-26 | Dainippon Sumitomo Pharma Co Ltd | Novel 1-aminocarbonylpiperidine derivative |
US8653131B2 (en) | 2008-08-22 | 2014-02-18 | Baxter Healthcare S.A. | Polymeric benzyl carbonate-derivatives |
JP2011256110A (en) * | 2008-09-30 | 2011-12-22 | Takeda Chem Ind Ltd | Manufacturing method of hexahydropyrroloquinoline |
JP5572154B2 (en) | 2009-03-31 | 2014-08-13 | 興和株式会社 | A prophylactic and / or therapeutic agent for anemia comprising a tetrahydroquinoline compound as an active ingredient |
GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
EP2955524A3 (en) | 2009-11-05 | 2016-03-23 | GlaxoSmithKline LLC | Novel process |
KR101920090B1 (en) | 2010-07-05 | 2018-11-19 | 이도르시아 파마슈티컬스 리미티드 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
US20140128367A1 (en) | 2011-06-17 | 2014-05-08 | Merck Sharp & Dohme Corp. | Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators |
EA026456B1 (en) | 2011-12-16 | 2017-04-28 | Атопикс Терапьютикс Лимитед | Pharmaceutical composition based on crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis |
CA2858328A1 (en) | 2011-12-21 | 2013-06-27 | Actelion Pharmaceuticals Ltd | Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
CN104428305A (en) | 2012-07-05 | 2015-03-18 | 埃科特莱茵药品有限公司 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators |
WO2017019858A1 (en) | 2015-07-30 | 2017-02-02 | The Trustees Of The University Of Pennsylvania | Single nucleotide polymorphic alleles of human dp-2 gene for detection of susceptibility to hair growth inhibition by pgd2 |
JOP20190105A1 (en) * | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | Magl inhibitors |
UA127357C2 (en) | 2018-04-18 | 2023-07-26 | Констеллатіон Фармацеутікалс, Інк. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CA3100977A1 (en) | 2018-05-21 | 2019-11-28 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
CN113201316B (en) * | 2021-04-25 | 2022-08-26 | 西南石油大学 | temperature/CO 2 pH multi-responsive emulsifier and emulsion and application thereof |
CN116425623B (en) * | 2023-04-10 | 2024-02-13 | 大连凯飞化学股份有限公司 | Method for synthesizing 3,5-dichloro-4-methylbenzoic acid by one-pot method |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP0101728A3 (en) * | 1998-03-31 | 2002-04-29 | Shionogi & Co | 5-hydroxybenzo[b]thiophene-3-carboxylic acid and their derivatives and methods for producing them |
DK1425270T3 (en) * | 2001-04-30 | 2006-07-03 | Pfizer Prod Inc | Methods and Intermediates for Preparation of 4-Aminoquinoline CETP Inhibitors |
JP2003321471A (en) * | 2002-04-30 | 2003-11-11 | Fuji Photo Film Co Ltd | Lactam compound and method of production for the same |
US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
EP1556047A4 (en) * | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | Pgd2 receptor antagonists for the treatment of inflammatory diseases |
AU2003269327A1 (en) * | 2002-10-21 | 2004-05-04 | Warner-Lambert Company Llc | Tetrahydroquinoline derivatives as crth2 antagonists |
AU2003289207A1 (en) * | 2002-12-06 | 2004-06-30 | Kyowa Hakko Kogyo Co., Ltd. | Anti-inflammatory agent |
EP1435356A1 (en) * | 2003-01-06 | 2004-07-07 | Warner-Lambert Company LLC | Quinoline derivatives as CRTH2 antagonists |
-
2005
- 2005-04-07 MX MXPA06011540A patent/MXPA06011540A/en not_active Application Discontinuation
- 2005-04-07 UA UAA200611678A patent/UA84749C2/en unknown
- 2005-04-07 BR BRPI0509668-5A patent/BRPI0509668A/en not_active IP Right Cessation
- 2005-04-07 CN CNA200580018590XA patent/CN101018770A/en active Pending
- 2005-04-07 AU AU2005233125A patent/AU2005233125A1/en not_active Withdrawn
- 2005-04-07 CA CA002561564A patent/CA2561564A1/en not_active Abandoned
- 2005-04-07 KR KR1020067023323A patent/KR20070002085A/en not_active Application Discontinuation
- 2005-04-07 AR ARP050101369A patent/AR048528A1/en unknown
- 2005-04-07 WO PCT/US2005/011643 patent/WO2005100321A1/en active Application Filing
- 2005-04-07 TW TW094111008A patent/TW200538127A/en unknown
- 2005-04-07 JP JP2007507467A patent/JP2007532555A/en active Pending
- 2005-04-07 EP EP05733968A patent/EP1740547A1/en not_active Withdrawn
- 2005-04-07 RU RU2006138603/04A patent/RU2006138603A/en not_active Application Discontinuation
-
2006
- 2006-09-27 IL IL178328A patent/IL178328A0/en unknown
- 2006-09-27 CR CR8659A patent/CR8659A/en not_active Application Discontinuation
- 2006-10-06 TN TNP2006000320A patent/TNSN06320A1/en unknown
- 2006-10-27 ZA ZA200608955A patent/ZA200608955B/en unknown
- 2006-11-02 MA MA29430A patent/MA28566B1/en unknown
- 2006-11-06 NO NO20065107A patent/NO20065107L/en not_active Application Discontinuation
- 2006-11-08 EC EC2006006977A patent/ECSP066977A/en unknown
-
2008
- 2008-01-10 CL CL200800069A patent/CL2008000069A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1740547A1 (en) | 2007-01-10 |
ECSP066977A (en) | 2006-12-29 |
KR20070002085A (en) | 2007-01-04 |
RU2006138603A (en) | 2008-05-20 |
MA28566B1 (en) | 2007-05-02 |
CR8659A (en) | 2007-06-08 |
NO20065107L (en) | 2006-12-01 |
MXPA06011540A (en) | 2007-01-26 |
IL178328A0 (en) | 2007-02-11 |
BRPI0509668A (en) | 2007-10-09 |
TW200538127A (en) | 2005-12-01 |
ZA200608955B (en) | 2009-05-27 |
WO2005100321A1 (en) | 2005-10-27 |
CL2008000069A1 (en) | 2008-05-16 |
TNSN06320A1 (en) | 2008-02-22 |
CN101018770A (en) | 2007-08-15 |
CA2561564A1 (en) | 2005-10-27 |
AR048528A1 (en) | 2006-05-03 |
JP2007532555A (en) | 2007-11-15 |
AU2005233125A1 (en) | 2005-10-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA84749C2 (en) | Normal;heading 1;heading 2;PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | |
WO2004032848A3 (en) | Pgd2 receptor antagonists for the treatment of inflammatory diseases | |
MX2007003335A (en) | Benzimidazole acetic acids exhibiting crth2 receptor antagonism and uses thereof. | |
NO20074961L (en) | Imidazopyridazinforbindelser | |
BRPI0408369A (en) | indole derivatives useful for treating disease | |
DE60005485D1 (en) | INDOLDER DERIVATIVES AND THEIR USE AS MCP-1 RECEPTOR ANTAGONISTS | |
NO20051503L (en) | Pyrazolopyridines and processes for the preparation and use of the same. | |
NO20055649L (en) | Substituted dihydroquinazoline with antivial properties | |
DE602004012858D1 (en) | 2-AMINOBENZOTHIAZOLE AS CB1 RECEPTOR INVERSE AGONISTS | |
CA2503900A1 (en) | Purine compounds and use thereof as cannabinoid receptor ligands | |
BR0315234A (en) | Indole derivatives as beta-2 agonists | |
EA200401309A1 (en) | TRYZE-SUBSTITUTED HETEROARILES AND METHODS OF THEIR RECEPTION AND APPLICATION | |
MX2007007220A (en) | Pyrazolone compounds as metabotropic glutamate receptor agonists for the treatment of neurological and psychiatric disorders. | |
TW200640869A (en) | PGD2 receptor antagonists for the treatment of inflammatory diseases | |
IL177291A0 (en) | Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists | |
EA200500173A1 (en) | 3,6-DISPOSABLE AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS ANTAGONISTS OF MUSCARIN RECEPTORS | |
MY141200A (en) | Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group | |
ATE478856T1 (en) | SPIROBENZODIOXOLS AND THEIR USE AS CB1 ANTAGONISTS | |
TW200624432A (en) | Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto | |
ATE323686T1 (en) | SUBSTITUTED 2-ARYLBENZAZOLES AND THEIR USE AS ANTITUMORAL AGENTS | |
BRPI0409393A (en) | compound, pharmaceutical composition, and methods for modulating chemokine receptor activity in a mammal for treating, ameliorating, controlling or reducing the risk of an inflammatory and immunoregulatory disorder or disease, and rheumatoid arthritis | |
RS20070095A (en) | Alkyliden-tetrahydronaphthalene derivatives, method for their production and their use as anti-inflammatory agents | |
WO2006114666A8 (en) | SUBSTITUTED ARYL 1,4-PYRAZlNE DERIVATIVES | |
EA200602081A1 (en) | PYRIDINE DERIVATIVES OF ALKYLOXINDOLS AS AGENTS ACTIVE AGAINST THE RECEPTOR 5-НТ7 | |
BR9607443A (en) | Compound of 4-aminotetrahydrobenzisoxazole or -isatiazole pharmaceutical composition and use of the compound |